-GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity

Press/Media

Period4 Nov 2020

Media coverage

1

Media coverage

  • Title-GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity
    Media name/outletENP Newswire
    Country/TerritoryUnited Kingdom
    Date4/11/20
    PersonsStephen C. Krieger
View all 1
View less